This Analyst Recently Issued Research Note On Organogenesis Holdings Inc. (ORGO)


As of Friday close, Organogenesis Holdings Inc.’s (NASDAQ:ORGO) stock was down -$0.11, moving down -5.21 percent to $2.00. The average number of shares traded per day over the past five days has been 5,249,920 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.28 fall in that time frame. In the last twenty days, the average volume was 2,375,465, while in the previous 50 days, it was 1,341,100.

Since last month, ORGO stock retreated -31.51%. Shares of the company fell to $2.00 on 03/17/23, the lowest level in the past month. A 52-week high of $8.27 was reached on 02/15/23 after having rallying from a 52-week low of $2.04. Since the beginning of this year, ORGO’s stock price has dropped by -25.65% or -$0.69, and marked a new high 6 times. However, the stock has declined by -75.82% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


ORGO stock investors should be aware that Organogenesis Holdings Inc. (ORGO) stock had its last reported insider trading activity 117 days ago on Nov 21. KATZ MICHAEL W, the 10% Owner of the company, purchased of 3,000 shares for $2.56 on Nov 21. It resulted in a $7,680 investment by the insider. KATZ MICHAEL W added 3,000 shares at an average price of $2.57 on Nov 18. The insider now owns 73,382 shares following the transaction. On Aug 12, Director Driscoll Michael Joseph bought 5,000 shares at $4.80 apiece. The transaction was valued at $24,000.

Valuation Metrics

Right now, Organogenesis Holdings Inc. (ORGO) has a P/E ratio of about 17.09. The stock’s beta is 1.38. Besides these, the trailing price-to-sales (P/S) ratio of 0.59, the price-to-book (PB) ratio of 0.99.

Financial Health

In the three months ended December 30, Organogenesis Holdings Inc.’s quick ratio stood at 2.60, while its current ratio was 3.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 0.25, and the total debt-to-equity ratio was 0.27. On the profitability front, the trailing twelve-month gross margin is 76.70% percent. In the year ended December 30, operating margins totaled 4.90%. Based on annual data, ORGO earned $345.87 million in gross profit and brought in $450.89 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 5.20%. Return on equity (ROE) for the past 12 months was 6.10%.

In Organogenesis Holdings Inc.’s quarter-end financial report for December 30, it reported total debt of $66.23 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ORGO’s revenue fell -12.26% to $116.86 million during the quarter, while net income inched up to $114.52 million. While analysts expected Organogenesis Holdings Inc. to report $0.05 quarterly earnings, the actual figure was $0.06 per share. During the quarter, the company generated $12.27 million in EBITDA. The liabilities of Organogenesis Holdings Inc. were 183.69 million at the end of its most recent quarter ended December 30, and its total debt was $130.71 million. The value of shareholders’ equity is $131.18 million.

Technical Picture

This quick technical analysis looks at Organogenesis Holdings Inc.’s (ORGO) price momentum. With a historical volatility rate of 25.74%, the RSI 9-day stood at 29.81% on 17 March.

With respect to its five-day moving average, the current Organogenesis Holdings Inc. price is down by -12.28% percent or -$0.28. At present, ORGO shares trade -27.27% below its 20-day simple moving average and -36.51% percent below its 100-day simple moving average. However, the stock is currently trading approximately -25.93% below its SMA50 and -64.35% below its SMA200.

Stochastic coefficient K was 8.90% and Stochastic coefficient D was 8.86%, while ATR was 0.18. Given the Stochastic reading of 0.00% for the 14-day period, the RSI (14) reading has been calculated as 35.06%. As of today, the MACD Oscillator reading stands at -0.12, while the 14-day reading stands at -0.24.

Analyst Ratings

Organogenesis Holdings Inc. downgraded its rating on Organogenesis Holdings Inc. (NASDAQ: ORGO) to a Neutral in a note to investors on November 10, 2022. The analysts firm previously had a Buy rating on the stock.Organogenesis Holdings Inc. (ORGO) has been rated Hold by analysts. According to 0 brokerage firms, ORGO is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Organogenesis Holdings Inc. stock as buy, with 0 recommending it as overweight.

With a median target price of $11.00, the current consensus forecast for the stock is $11.00 – $11.00. Based on these forecasts, analysts predict Organogenesis Holdings Inc. (ORGO) will achieve an average price target of $11.00.


Please enter your comment!
Please enter your name here